Craif Was Featured in the CRDS Research Report as a Major Biotech Startup in Japan
Ryuichi Onose, CEO of Craif, Has Been Selected as “Forbes 30 Under 30 Asia 2021” in the Healthcare & Science Field
Icaria Closed of Series A Funding Round and Company Name Change to “Craif”